Abstracts Archive - Page 1863 of 2425 - ACR Meeting Abstracts

Abstract Number: 2842 • 2014 ACR/ARHP Annual Meeting
An Anti CD123 Monoclonal Antibody (CSL362) Depletes Plasmacytoid Dendritic Cells and Inhibits CpG Upregulated IFNα Production and IFNα-Inducible Gene Expression in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus
Shereen Oon^1,2,3, Nicholas Wilson^4,5 and Ian Wicks^1,2,3, ¹Inflammation, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, ²Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, ³Medical Biology, The University of Melbourne, Melbourne, Australia, ⁴Cell Biology and Physiology, CSL Limited, Melbourne, Australia, ⁵Honorary appointment, The University of Melbourne, Melbourne, Australia
Background/Purpose Plasmacytoid dendritic cells (pDCs) contribute to systemic lupus erythematosus (SLE) pathogenesis by producing Type 1 interferon (IFN), most likely induced by endosomal Toll like…
Abstract Number: 2843 • 2014 ACR/ARHP Annual Meeting
SLE Patients Carrying a Disease-Associated PTPN22 R620W Variant Show Reduced Interferon-Inducing Capacity
Yaya Wang¹, David Ewart², Ami Yamamoto², Emily C. Baechler¹, Parastoo Fazeli³ and Erik J. Peterson², ¹Medicine, University of Minnesota, Minneapolis, MN, ²University of Minnesota, Minneapolis, MN, ³Division of Rheumatic and Autoimmune Diseases, University of Minnesota, Minneapolis, MN
Background/Purpose Type 1 interferons (IFN) are implicated in the pathogenesis of systemic lupus erythematosus (SLE). Increased expression of IFN-regulated genes, termed the IFN-signature, correlates with…
Abstract Number: 2844 • 2014 ACR/ARHP Annual Meeting
Intracellular Complement C3 Is Exposed on the Cell Surface upon Apoptosis Induction and Participates in the Clearance of Apoptotic Cells By Phagocytes
Lucrezia Colonna¹, Christian Lood¹, YuFeng Peng², Xizhang Sun³, Lena Tanaka³, Sandip Panicker⁴ and Keith B. Elkon³, ¹Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, University of Washington, Seattle, WA, ³Division of Rheumatology, University of Washington, Seattle, WA, ⁴True North Therapeutics, South San Francisco, CA
Background/Purpose The complement system has been viewed as a predominantly serum-derived host defense mechanism with multiple functions, including clearance of apoptotic cells. Defective function of…
Abstract Number: 2845 • 2014 ACR/ARHP Annual Meeting
Altered Plasticity of Inflammatory CD4 T Cells Contributing to Th17 Shift in Rheumatoid Arthritis
Jan Leipe, Fausto Pirronello, Simon Hermann, Matthias Witt, Hendrik Schulze-Koops and Alla Skapenko, Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany
Background/Purpose Whereas T helper (Th) cell subsets were previously regarded as irreversibly differentiated endpoints, evidence suggests that Th cell differentiation is a plastic process in…
Abstract Number: 2846 • 2014 ACR/ARHP Annual Meeting
CaMK4 Inhibition Ameliorates the Development of Th17 Driven Inflammatory Diseases By Preventing Recruitment of IL-17 Producing Cells to Target Organs
Tomohiro Koga^1,2, Kotaro Otomo², Masayuki Mizui³, Nobuya Yoshida⁴, José C. Crispin², Atsushi Kawakami¹ and George C. Tsokos⁵, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Department of Medicine,, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁵Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: IL-17 producing T helper (Th17) cells have been closely associated with the development of organ damage in inflammatory and autoimmune diseases. We have previously…
Abstract Number: 2847 • 2014 ACR/ARHP Annual Meeting
Survivin Co-Ordinates Formation of Follicular T-Cells in Rheumatoid Arthritis
Maria Bokarewa¹, Karin Andersson², Malin Erlandsson², Mattias Svensson², Nicola Cavallini³ and Mikael Brisslert², ¹Guldhedsgatan 10, University of Goteborg, Goteborg, Sweden, ²Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ³Rheumatology and Inflammation Research, University of Göteborg, Göteborg, Sweden
Background/Purpose Survivin is a proto-oncogene that regulates cell division and apoptosis. Recently, survivin has emerged as a biomarker of persistently active and joint destructive rheumatoid…
Abstract Number: 2848 • 2014 ACR/ARHP Annual Meeting
T-Cell Signaling Defects Can be Corrected By Manipulating ‘TCR Signal Fine-Tuning Molecules’ That Are Altered Due to Increased Ubiquitination in Systemic Autoimmune Disease
Julia Pinkhasov¹ and Ram Raj Singh^1,2,3,4, ¹Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, UCLA, Los Angeles, CA, ²Interdepartmental Program in Molecular Toxicology, UCLA, Los Angeles, CA, ³Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, ⁴Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA
Background/Purpose . T-cell selection in the thymus is primarily determined by the avidity of T cell receptor (TCR) for self-ligand-MHC. Since this process is dependent…
Abstract Number: 2849 • 2014 ACR/ARHP Annual Meeting
Involvement of CD8⁺ T Cells in the Pathogenesis of Giant Cell Arteritis and Polymyalgia Rheumatica
Maxime Samson¹, Sylvain Audia¹, Malika Trad², Marion Ciudad², Hervé Devilliers³, Alexandrine Gautheron², Valérie Quipourt⁴, Francois Maurier⁵, Nadine Meaux Ruault⁶, Patrick Manckoundia⁴, Paul Ornetti⁷, Jean-Francis Maillefert⁸, Jean-François Besancenot³, Christophe Ferrand⁹, Philippe Saas⁹, Laurent Martin¹⁰, Nona Janikashvili² and Bernard Bonnotte¹, ¹Dijon University Hospital, INSERM UMR 1098, Besançon ; University of Burgundy, Faculty of Medicine, IFR100 ; Department of Internal Medicine and Clinical Immunology, Dijon, France, ²University of Burgundy, Faculty of Medicine, IFR100, INSERM UMR 1098, Besançon, Dijon, France, ³Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ⁴Dijon University Hospital, Department of Geriatric Internal Medicine, Dijon, France, ⁵HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁶Besançon University Hospital, Department of Internal Medicine, Besançon, France, ⁷Dijon University Hospital, Department of Rheumatology, Dijon, France, ⁸Rheumatology, University Hospital Dijon, Dijon, France, ⁹Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France, ¹⁰Dijon University Hospital, INSERM UMR 1098, Besançon ; University of Burgundy, Faculty of Medicine, IFR100 ; Department of Pathology, Dijon, France
Background/Purpose Previous studies have demonstrated the implication of CD4+ T cells, especially T helper (Th1) and Th17 cells, in the pathogenesis of giant cell arteritis (GCA)…
Abstract Number: 2850 • 2014 ACR/ARHP Annual Meeting
MiR-125a Is Critical Regulator for Controlling Autoimmunity in Multiple Autoimmune Diseases through Stabilizing Treg Mediated Immune Homeostasis
Wan Pan^1,2, Shu Zhu², Dai Dai², John Harley³ and Nan Shen^1,2,3, ¹Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, ²Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, ³The Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America, Cincinnati, OH
Background/Purpose Although different autoimmune diseases show distinct clinical phenotypes, common cellular and molecular immune pathways have been shown to be intimately involved in the autoimmune…
Abstract Number: 2851 • 2014 ACR/ARHP Annual Meeting
The Relationship of ARMS2 Genotype with Idiopathic Inflammatory Vasculitis
Christopher Mecoli¹, Fan Wang², Christopher Pappas³, Peter C. Grayson⁴, David Cuthbertson⁵, Simon Carette⁶, Christian Pagnoux⁶, Gary S. Hoffman⁷, Nader A. Khalidi⁸, Curry L. Koening⁹, Carol A. Langford¹⁰, Carol McAlear¹¹, Paul A. Monach¹², Larry W. Moreland¹³, Philip Seo¹⁴, Ulrich Specks¹⁵, Steven R. Ytterberg¹⁶, Rui Feng¹⁷, Gregory Hageman³ and Peter A. Merkel¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, OK, ³University of Utah School of Medicine, Salt Lake City, UT, ⁴NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ⁵Department of Biostatistics, University of South Florida, Tampa, FL, ⁶Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Division of Rheumatology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, ⁹Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹⁰Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹¹Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ¹²Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ¹³Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹⁵Frederichs Dr NW, Mayo Clinic, Rochester, MN, ¹⁶Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁷Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Patients with age-related macular degeneration (AMD), a leading cause of irreversible blindness, have a 10-fold increased prevalence of abdominal aortic aneurysms. Single nucleotide polymorphisms…
Abstract Number: 2852 • 2014 ACR/ARHP Annual Meeting
Evaluation of KIR3DL1/KIR3DS1 Association with Behçet’s Disease in Turkish Individuals
Burak Erer¹, Elaine F. Remmers¹, Masaki Takeuchi¹, Colleen Satorius², Duran Ustek³, Ilknur Tugal-tutkun⁴, Emire Seyahi⁵, Yilmaz Ozyazgan⁶, Ahmet Gul⁴, Daniel L. Kastner⁷ and Michael J. Ombrello⁸, ¹Medical Genetics Branch, Inflammation Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey, ⁴Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁵Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ⁶Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey, ⁷Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, ⁸Translational Genetics and Genomics Unit, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: The Behçet’s disease (BD)-associated HLA-B type, HLA-B*51 (B*51), is a ligand for a pair of allelic killer immunoglobulin-like receptors (KIR) present on cytotoxic cells…
Abstract Number: 2853 • 2014 ACR/ARHP Annual Meeting
Comparative Study of Infliximab Versus Adalimumab in Patients with Refractory Uveitis Due to Behçet´s Disease. Multicenter Study of 125 Cases
Leyre Riancho-Zarrabeitia¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Paz Rodríguez-Cundín², Emma Beltrán³, Juan Sánchez Bursón Sr.⁴, Marina Mesquida⁵, Alfredo Adan⁵, M. Victoria Hernández⁶, Marisa Hernandez Grafella⁷, Elia Valls Pascual⁸, Lucía Martinez-Costa⁹, Agusti Sellas-Fernandez¹⁰, Miguel Cordero-Coma¹¹, Manuel Díaz-Llopis¹², Roberto Gallego¹², Jose Luis García Serrano¹³, Norberto Ortego-Centeno¹⁴, Jose M Herreras¹⁵, Alejandro Fonollosa¹⁶, Angel M. Garcia-Aparicio¹⁷, Olga Maiz Alonso¹⁸, Ana Blanco¹⁹, Ignacio Torre Salaberri²⁰, Cruz Fernández- Espartero²¹, Vega Jovani²², Diana Peiteado²³, Esperanza Pato²⁴, Juan Cruz²⁵, Carlos Férnandez Cid²⁶, Elena Aurrecoechea²⁷, Miriam García-Arias²⁸, Miguel Angel Caracuel-Ruiz²⁹, Carlos Alberto Montilla Morales³⁰, Antonio Atanes-Sandoval³¹, Félix Francisco³², Santos Insua³³, Senen González-Suárez³⁴, Maria Amalia Sanchez Andrade³⁵, Fernando Gamero³⁶, Luis Francisco Linares Ferrando³⁷, Fredeswinda Romero³⁸, A. Javier García-González³⁹, Raquel Almodóvar González⁴⁰, Enrique Minguez⁴¹, Carmen Carrasco Cubero⁴², Alejandro Olive⁴³, Julio Vázquez⁴⁴, Oscar Ruiz Moreno⁴⁵, Fernando Jiménez-Zorzo⁴⁵, Javier Manero⁴⁵, Santiago MuÑoz Fernandez⁴⁶, Javier Rueda-Gotor¹, Trinitario Pina¹, Montserrat Santos-Gómez¹ and Miguel A. González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Preventive Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁴Rheumatology. Hospital de Valme., Sevilla, Spain, ⁵Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁶Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, ⁷Ophthalmology. Hospital General universitario de Valencia, Valencia, Spain, ⁸Rheumatology. Hospital Peset, Valencia, Spain, ⁹Ophthalmology. Hospital Peset, Valencia, Spain, ¹⁰H. Vall d'Hebron, Barcelona, Spain, ¹¹Ophthalmology, Hospital de León. Spain, León, Spain, ¹²Ophthalmology, Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ¹³Ophthalmology. Hospital San Cecilio, Granada, Spain, ¹⁴Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹⁵Ophthalmology. Hospital Universitario, IOBA, Valladolid, Spain, ¹⁶Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, ¹⁷Rheumatology, Virgen de la Salud Hospital, Toledo, Spain, ¹⁸Rheumatology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ¹⁹Ophthalmology. Hospital Donosti, San Sebastián, Spain, ²⁰Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ²¹Rheumatology, Hospital Universitario de Móstoles. Madrid. Spain, Madrid, Spain, ²²Rheumatology. Hospital General de Alicante, Alicante, Spain, ²³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²⁴Rheumatology. Hospital Clínico San Carlos, Madrid, Spain, ²⁵Rheumatology. Hospital de Pontevedra, Pontevedra, Spain, ²⁶Ophthalmology. Hospital de Pontevedra, Pontevedra, Spain, ²⁷Hospital Sierrallana. Torrelavega, Torrelavega, Spain, ²⁸Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²⁹Plaza Cruz Roja, 1, H. Reina Sofia, Cordoba, Spain, ³⁰Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ³¹Rheumatology Division. C. Hospitalario Universitario A Coruña, A Coruña, Spain, ³²Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ³³Rheumatology. Hospital Universitario Santiago de Compostela, A Coruña, Spain, ³⁴Rheumatology. Hospital Cabueñes, Gijón, Spain, ³⁵Hosp. Lucus Augusti, Lugo, Spain, ³⁶Rheumatology. Hospital San Pedro Alcantara, Cáceres, Spain, ³⁷Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ³⁸Rheumatology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ³⁹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ⁴⁰Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ⁴¹Ophthalmology. Hospital Clínico de Zaragoza, Zaragoza, Spain, ⁴²Rheumatology, Hospital de Merida, Mérida, Spain, ⁴³Rheumatology Service, Germans Trias Pujol Hospital, Barcelona, Spain, ⁴⁴Rheumatology. Hospital de Ferrol, A Coruña, Spain, ⁴⁵Ophthalmology and Rheumatology. Hospital Miguel Servet Zaragoza, Spain, Zaragoza, Spain, ⁴⁶Sección de Reumatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain
Background/Purpose: To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as first biologic drug in refractory uveitis due to Behçet's disease (BD) for 1-year…
Abstract Number: 2854 • 2014 ACR/ARHP Annual Meeting
Effect of Apremilast on Quality of Life and Physical Function in Patients with Behçet’s Syndrome
Gulen Hatemi¹, Melike Melikoglu¹, Recep Tunc², Cengiz Korkmaz³, Banu Turgut Ozturk⁴, Cem Mat⁵, Peter A. Merkel⁶, Kenneth Calamia⁷, Lilia Pineda⁸, Ziqi Liu⁸, Randall M. Stevens⁸, Hasan Yazici¹ and Yusuf Yazici⁹, ¹Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ²Necmettin Erbakan University, Meram Medical Faculty,Division of Rheumatology, Konya, Turkey, ³EskiÅŸehir Osmangazi University, EskiÅŸehir, Turkey, ⁴Selçuk University, Konya, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Dermatology, Istanbul, Turkey, ⁶Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁷Administration, Mayo Clinic Health System in Waycross, Waycross, GA, ⁸Celgene Corporation, Warren, NJ, ⁹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: The oral ulcers in Behçet’s syndrome (BS) can be painful, causing difficulty in eating and speaking, and can impair the quality of life. Apremilast…
Abstract Number: 2815 • 2014 ACR/ARHP Annual Meeting
Better Functional Ability with Less Biologicals 2 years after Induction with Combination DMARD Therapy versus methotrexate Monotherapy
T. Martijn Kuijper¹, J.J. Luime¹, P.H.P. de Jong², A. H. Gerards³, D. van Zeben⁴, I. Tchetverikov⁵, P.B.J. de Sonnaville⁶, M. van Krugten⁷, B. Grillet⁸, J.M.W. Hazes⁹ and A.E.a.M. Weel^10,11, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁴Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁵Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁶Rheumatology, Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, ⁷Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands, ⁸Rheumatology, ZorgSaam Hospital, Terneuzen, Netherlands, ⁹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ¹⁰Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ¹¹Rheumatology, MD, PhD, Rotterdam, Netherlands
Background/Purpose: To assess differences in frequency of biological therapy use and functional ability in early RA patients two years after starting induction therapy according to…
Abstract Number: 2816 • 2014 ACR/ARHP Annual Meeting
Distinctive DNA Methylome Signatures in Early Rheumatoid Arthritis (RA) Synoviocytes Compared with Longstanding (RA) and Other Inflammatory Arthritides
Rizi Ai¹, John W. Whitaker², David L. Boyle³, Paul Peter Tak⁴, Danielle M. Gerlag⁵, Wei Wang⁶ and Gary S. Firestein³, ¹Chemistry, UC San Diego, La Jolla, CA, ²860 island ave, UCSD, San Diego, CA, ³Division of Rheumatology, Allergy and Immunology, University of California at San Diego School of Medicine, La Jolla, CA, ⁴Academic Medical Center / University of Amsterdam, Department of Clinical Immunology and Rheumatology & GlaxoSmithKline, Amsterdam, Netherlands, ⁵Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Chemistry, UCSD, La Jolla, CA
Background/Purpose: Epigenetics influences pathogenic mechanisms in autoimmunity. Recently, a stable RA DNA methylation signature in fibroblast-like synoviocytes (FLS) was defined in 2375 genes. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].